BioNexus Gene Lab CEO urges Malaysia-China biotech co-development at May 21 forum

BioNexus Gene Lab Corp

CEO Sam Tan spoke at the 2026 China-Malaysia Economic Cooperation Outlook Forum in Kuala Lumpur on May 21, 2026.
Tan called for moving biotechnology collaboration beyond trade into co-development, clinical validation, and commercialization.
Company highlighted its Fidelion Diagnostics Pte. Ltd. and VitaGuard MRD platform as a model for cross-border biotechnology structuring.
Proposed pillars include accelerated clinical validation for precision oncology, specialized diagnostics infrastructure, and AI-integrated healthcare under regional data rules.
No specific financial guidance, deal value, or other material quantitative changes disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.